125 related articles for article (PubMed ID: 20136784)
1. mTOR inhibition: the learning curve in kidney transplantation.
Weir MR; Diekmann F; Flechner SM; Lebranchu Y; Mandelbrot DA; Oberbauer R; Kahan BD
Transpl Int; 2010 May; 23(5):447-60. PubMed ID: 20136784
[TBL] [Abstract][Full Text] [Related]
2. mTOR inhibitor/proliferation signal inhibitors: entering or leaving the field?
Rostaing L; Kamar N
J Nephrol; 2010; 23(2):133-42. PubMed ID: 20155724
[TBL] [Abstract][Full Text] [Related]
3. [The use of mTOR inhibitors in kidney transplantation: who are the best patients and how should these inhibitors be used?].
Büchler M
Nephrol Ther; 2009 Dec; 5 Suppl 6():S390-4. PubMed ID: 20129451
[TBL] [Abstract][Full Text] [Related]
4. Immunosuppression using the mammalian target of rapamycin (mTOR) inhibitor everolimus: pilot study shows significant cognitive and affective improvement.
Lang UE; Heger J; Willbring M; Domula M; Matschke K; Tugtekin SM
Transplant Proc; 2009 Dec; 41(10):4285-8. PubMed ID: 20005385
[TBL] [Abstract][Full Text] [Related]
5. Rescue immunosuppression with mammalian target of rapamycin inhibitor drugs in liver transplantation.
Mártinez JM; Pulido LB; Bellido CB; Usero DD; Aguilar LT; Moreno JL; Artacho GS; Díez-Canedo JS; Gómez LM; Bravo MA
Transplant Proc; 2010 Mar; 42(2):641-3. PubMed ID: 20304212
[TBL] [Abstract][Full Text] [Related]
6. Bladder cancer in patients after organ transplantation.
Wallerand H; Ravaud A; Ferrière JM
Curr Opin Urol; 2010 Sep; 20(5):432-6. PubMed ID: 20644482
[TBL] [Abstract][Full Text] [Related]
7. [Antitumoral effect of proliferation signal inhibitors].
Dumortier J
Gastroenterol Clin Biol; 2009 Nov; 33 Suppl 4():S263-7. PubMed ID: 20004333
[TBL] [Abstract][Full Text] [Related]
8. The impact of mTOR inhibitors on the development of malignancy.
Geissler EK
Transplant Proc; 2008 Dec; 40(10 Suppl):S32-5. PubMed ID: 19100904
[TBL] [Abstract][Full Text] [Related]
9. Is there a role for proliferation signal/mTOR inhibitors in the prevention and treatment of de novo malignancies after heart transplantation? Lessons learned from renal transplantation and oncology.
Valantine H
J Heart Lung Transplant; 2007 Jun; 26(6):557-64. PubMed ID: 17543777
[TBL] [Abstract][Full Text] [Related]
10. A spectrophotometric assay for routine measurement of mammalian target of rapamycin activity in cell lysates.
Dekter HE; Romijn FP; Temmink WP; van Pelt J; de Fijter JW; Smit NP
Anal Biochem; 2010 Aug; 403(1-2):79-87. PubMed ID: 20417611
[TBL] [Abstract][Full Text] [Related]
11. Maximizing the clinical outcome with mTOR inhibitors in the renal transplant recipient: defining the role of calcineurin inhibitors.
Nashan B
Transpl Int; 2004 Jul; 17(6):279-85. PubMed ID: 15221123
[TBL] [Abstract][Full Text] [Related]
12. Use of proliferation signal inhibitors in the management of post-transplant malignancies--clinical guidance.
Campistol JM; Albanell J; Arns W; Boletis I; Dantal J; de Fijter JW; Mortensen SA; Neumayer HH; Øyen O; Pascual J; Pohanka E; Schena FP; Serón D; Sparacino V; Chapman JR
Nephrol Dial Transplant; 2007 May; 22 Suppl 1():i36-41. PubMed ID: 17456617
[TBL] [Abstract][Full Text] [Related]
13. Drug insight: maintenance immunosuppression in kidney transplant recipients.
Samaniego M; Becker BN; Djamali A
Nat Clin Pract Nephrol; 2006 Dec; 2(12):688-99. PubMed ID: 17124526
[TBL] [Abstract][Full Text] [Related]
14. De novo immunosuppression with mammalian target of rapamycin inhibitors and posttransplantation malignancy in focus.
Flechner S; Friend P; Campistol J; Weir M; Diekmann F; Russ G
Transplant Proc; 2009; 41(6 Suppl):S42-4. PubMed ID: 19651296
[No Abstract] [Full Text] [Related]
15. Can mTOR inhibitors reduce the risk of late kidney allograft failure?
Ponticelli C
Transpl Int; 2008 Jan; 21(1):2-10. PubMed ID: 17635837
[TBL] [Abstract][Full Text] [Related]
16. Calcineurin inhibitor-free immunosuppression in kidney transplantation.
Guerra G; Srinivas TR; Meier-Kriesche HU
Transpl Int; 2007 Oct; 20(10):813-27. PubMed ID: 17645419
[TBL] [Abstract][Full Text] [Related]
17. Functional consequences of mTOR inhibition.
Sudarsanam S; Johnson DE
Curr Opin Drug Discov Devel; 2010 Jan; 13(1):31-40. PubMed ID: 20047144
[TBL] [Abstract][Full Text] [Related]
18. [Minimize kidney failure in transplantation patients with proliferation signal inhibitors].
Glowacki F; Dharancy S; Noël C; Hazzan M
Gastroenterol Clin Biol; 2009 Nov; 33 Suppl 4():S253-6. PubMed ID: 20004331
[TBL] [Abstract][Full Text] [Related]
19. Evidence for immunosuppression in lung transplantation.
Hopkins PM; McNeil K
Curr Opin Organ Transplant; 2008 Oct; 13(5):477-83. PubMed ID: 19060529
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in the development of selective, ATP-competitive inhibitors of mTOR.
Richard DJ; Verheijen JC; Zask A
Curr Opin Drug Discov Devel; 2010 Jul; 13(4):428-40. PubMed ID: 20597028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
